// App-Quantinova.ai

e15003 : Phase 2 of intra-arterial hepatic (IAH) bevacizumab with systemic chemotherapy (CT) in second line treatment of liver metastases of colorectal cancer (LMCRC).

Researchers

Presenter

  • Michel Ducreux

Principal Investigators

  • Olivier Glehen

  • Gabrielle Tergemina-Clain

  • Denis Michel Smith

  • Benjamin Lacas

  • Valerie Boige

  • Guillaume Passot

  • David Malka

  • Jean-Pierre Pignon

  • Eric Dupont-Bierre

  • Rosine Guimbaud

Medical Centers

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • Gustave-Roussy Cancer Campus, Biostatistics and Epidemiology unit, Villejuif, France

  • Hopital Saint-Andre, Bordeaux, France

  • Gustave Roussy, Villejuif, France

  • Service d'Oncologie Digestive, Gustave Roussy, Villejuif, France

  • Hospices Civils de Lyon, Lyon, France

  • Centre Hospitalier Saint Gregoire, Rennes, France

  • CHU Toulouse, Toulouse, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Secondary liver cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

  • Bevacizumab

  • Oxaliplatin

  • Irinotecan

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01677884

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved